Current clinical trials have used similar antigens on the surface of AML stem cells as used for antibodies, including CD33, CD123, and CLL‐1 (Fig. 4), but given the increased toxicity with this technology, there is a strong focus on developing CAR‐T‐cell therapy allowing for rapid on and off switching [113]. The gene discussed is CD33; the disease is acute myeloid leukemia.